ENB THERAPEUTICS

Many patients rapidly develop drug resistance to approved cancer therapies.
A high percentage of patients do not respond at all to cutting edge cancer immunotherapy.

There is little hope for cancers that have spread to the brain.

Learn More

A New era in cancer therapy

ENB Therapeutics solves these problems with pipeline drugs to treat cancer that has spread to brain. Our therapies bypass mechanisms of drug resistance seen with other therapies. Our studies predict that many patients with the most challenging cancers should respond to our therapies.

The Challenge

There are few therapeutic options for cancers that have spread to the brain. Many patients rapidly develop drug resistance to commonly used cancer therapies. A high percentage of patients do not respond at all to cutting edge cancer immunotherapy. ENB Therapeutics is breaking through barriers that prevent patients from responding to treatment.

Targeting Cancer’s Master Switch

Almost 20 years ago, our team discovered that melanoma spreads through the body because a switch that should only be turned on in the developing embryo, gets turned back on in melanoma patients. This switch tells melanoma cells to leave the skin and travel to distant sites, especially the brain. It also tells many types of different cancers to multiply continuously and hides them from immune system attack. Our therapies turn off this switch, stopping the cancer cell in its tracks and causing it to die. They also stimulate the body’s immune system to attack and kill the cancer.

The Time is Right

We are developing small molecules that turn off cancer’s master switch: The endothelin B receptor (ETBR). Our therapies have shown efficacy in preclinical studies in treating melanoma, glioblastoma, squamous cell carcinoma and  ovarian cancer among others. Our therapies should also help patients with pancreatic cancer and  cancers that have spread to the brain.  We have developed a simple and cost effective screening test to help determine those most likely to respond to our treatments. It is now time to bring these agents to those in need.